

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 4 September 2023 in relation to, among others, Mr. Cai’s Share Options, the Underlying Transaction and the Whitewash Waiver (the “**Announcement**”). Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of Mr. Cai’s Share Options; (ii) further details of the Underlying Transaction and the Whitewash Waiver; (iii) the letter from the Independent Board Committee; (iv) the recommendations from the independent financial adviser on the Underlying Transaction and the Whitewash Waiver; and (v) a notice convening the EGM, shall be despatched to the Shareholders within 21 days of the date of the Announcement pursuant to Rule 8.2 of the Takeovers Code, i.e. on or before 25 September 2023.

Given (a) additional time is required for the preparation and finalisation of certain information to be included in the Circular, including, among other things, the letter from the independent financial adviser, the indebtedness statement of the Group and the statement of no material change to the financial or trading position or outlook of the Group as required under the Takeovers Code; and (b) the upcoming mid-autumn festival which falls on 29 September 2023, and 30 September 2023 and 2 October 2023 are both public holidays, it is not practicable for the Circular to be despatched on or before 25 September 2023 nor in the week of 25 September 2023 or 2 October 2023.

An application has been made to the Executive for a waiver from strict compliance with Rule 8.2 of the Takeovers Code and to extend the time for the despatch of the Circular from 25 September 2023 to 9 October 2023 unless further extension is granted by the Executive. The Executive has indicated that it is minded to grant its consent for such extension.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 22 September 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.